New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Heatwurx Inc.

PCSA

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.67 0.03 −1.76%
Market cap
$4.8M
P/E
n/m
Fwd P/E FY16e
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.4×
Payout ratio
—

Ratios over time FY16 to FY25

Returns on capital

ROIC was -21694.3% in FY25, the lowest of these ten years. ROE, at -373.0%, is far above it because equity is small against the capital the business uses.

ROEROIC
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
ROE−1329.5%−140.6%−74.8%−43.6%−93.1%−47.2%−166.4%−178.5%−354.5%−373.0%
ROIC−682.4%0.0%−34.5%−29.7%−125.0%−84.4%−1309.2%−2530.3%−1491.8%−21694.3%

Debt

Net debt is 0.40× a year’s EBITDA. Debt is 0.00× equity, against 6.56× in FY17.

Debt / equityNet debt / EBITDA
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Debt / equity0.0×6.6×0.0×0.1×0.0×0.0×0.0×0.0×0.0×0.0×
Net debt / EBITDA1.1×0.2×0.3×−0.1×1.1×1.5×0.3×0.4×0.1×0.4×

Cash cycle, in days

Customers pay in 0 days and suppliers are paid in 0. Cash is tied up for 0 days between paying for goods and being paid.

Cash cycleDays to pay suppliersDays to be paid
FY17FY18FY20FY21
Cash cycle0000
Days to pay suppliers0000
Days to be paid0000

Per share, from FY16

Since FY16, per share: book value has fallen 36.9% a year.

Book value
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Book value1.0×0.1×3.4×2.7×5.7×3.1×0.9×0.4×0.1×0.0×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Current Ratio
2.54 1.23 7.71 8.40 18.87 13.27 0.85 3.13 1.14 23.92
Net Debt/EBITDA
0.40 0.10 0.41 0.34 1.45 1.07 (0.08) 0.33 0.22 1.09
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.18% 8.73% 1.84% 82.09% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.12 0.02 6.56 0.00
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF/Net income
0.84 0.95 0.73 0.35 0.76 0.22 0.71 0.98 0.89 1.12
Capex/Depreciation
(708.33) (4.00) (14.00) 0.00 0.00 0.00 0.00 (2.65) (0.82) (17.00)
Interest Coverage
— — — (200.17) (1,011.12) (53.85) (107.23) (28.07) (30.50) (427.00)
ROE
(372.96%) (354.51%) (178.52%) (166.43%) (47.20%) (93.14%) (43.64%) (74.75%) (140.61%) (1,329.47%)
ROA
(245.66%) (262.87%) (154.40%) (156.34%) (44.23%) (79.86%) (33.08%) (48.69%) (69.42%) (155.28%)
ROIC
(21,694.32%) (1,491.78%) (2,530.28%) (1,309.15%) (84.38%) (125.00%) (29.74%) (34.53%) 0.00% (682.35%)
Return on Tangible Assets
(394.48%) (3,370.34%) (226.76%) (360.10%) (65.56%) (96.21%) 2,200.97% (270.45%) (491.60%) (84.76%)
Average Days of Receivables
— — — — 0.00 0.00 — 0.00 0.00 —
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.15 0.00 0.00 0.00 0.30 0.35 0.89 0.84 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% — —
Free Cash Flow per Share
(9.35) (91.90) (153.64) (298.29) (284.88) (209.55) (247.76) (348.62) (180.13) (259.38)
Cash per Share
4.23 9.73 89.64 201.98 539.14 1,027.75 62.30 162.71 306.17 248.95
Shareholders Equity per Share
4.26 13.86 95.03 232.01 832.85 1,529.30 721.86 906.64 40.13 269.90
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
4.26 13.86 95.03 232.01 832.85 1,529.30 721.86 906.64 40.13 269.90
Free Cash Flow
(12.24) (11.25) (8.07) (9.61) (8.72) (3.14) (2.75) (3.73) (1.68) (2.18)
Working Capital
3.43 0.35 4.90 7.39 17.36 14.98 (0.18) 1.37 0.35 2.24
Capital Expenditures
(0.85) 0.00 0.00 — — — — (0.02) (0.02) (0.02)
Net Current Asset Value
3.43 0.35 4.84 7.24 17.35 13.93 (1.86) (0.76) 0.34 2.24
Other line items
Quick Ratio
2.48 0.78 6.44 6.51 17.06 12.69 0.58 2.73 1.12 21.40
Depreciation/Fixed assets
0.32 0.16 0.08 3.97 10.66 1,607.60 90.52 0.48 0.98 0.06
Cash ROIC
(110.09%) (389.55%) (83.20%) (68.73%) (20.76%) (8.19%) (28.49%) (31.96%) (29.55%) (49.99%)
Accounts Receivable Turnover
— — — — 0.00 0.00 — 0.00 0.00 —
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Revenue per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF per Share
(8.70) (91.87) (153.59) (298.29) (284.88) (209.55) (247.76) (346.53) (177.91) (256.55)
Capex per Share
(0.65) (0.03) (0.05) 0.00 0.00 0.00 0.00 (2.08) (2.22) (2.83)
Average Receivables
— — — — 0.07 0.05 — 0.04 0.03 —
Average Payables
0.97 0.60 0.32 0.27 0.27 0.20 0.18 0.17 0.03 0.09
Average Inventory
— — — — — — — — 0.00 0.00
Average Assets
5.52 4.51 7.20 17.54 25.84 18.05 11.68 7.73 2.67 1.23
Average Common Equity
3.64 3.34 6.23 16.48 24.21 15.48 8.86 5.04 1.32 0.14
Capex to Sales
0.00 0.00 0.00 — — — — 0.00 0.00 0.00

Fold the line items

Columns are period end dates · fundamentals updated 18 Nov 2026